Taken together, these results confirm that GSDMB enhances the pro-survival autophagy in response to lapatinib in HER2 + breast and gastric cancer cells, and thus GSDMB-over-expressing cells are more sensitive to the addition of autophagy inhibitors both in the early response to HER2-targeted treatment and in drug resistant cells. Here, ERBB2 is linked to gastric cancer.